Temozolomide for Metastatic Melanoma Treatment
Author Information
Author(s): Quirbt I. MD, Verma S. MD, Petrella T. MD, Bak K. BA, Charette M. BSc
Primary Institution: Cancer Care Ontario’s Program in Evidence-Based Care
Hypothesis
What is the role of single-agent temozolomide in the treatment of patients with metastatic melanoma?
Conclusion
Temozolomide is a reasonable treatment option for patients with unresectable metastatic melanoma, but its combination with interferon-α or thalidomide is not recommended at this time.
Supporting Evidence
- Temozolomide has shown efficacy equal to that of dacarbazine in a randomized phase iii trial.
- The addition of interferon-α to temozolomide resulted in a higher response rate but did not improve overall survival.
- Temozolomide is a convenient oral treatment that penetrates the blood-brain barrier.
Takeaway
Temozolomide is a pill that can help people with a serious skin cancer called melanoma, especially if it has spread to other parts of the body.
Methodology
Evidence was selected and reviewed by members of the Melanoma Disease Site Group and methodologists, with external review from Ontario practitioners.
Potential Biases
Potential conflicts of interest were disclosed by members of the Melanoma Disease Site Group.
Limitations
The evidence on the roles of interferon and thalidomide in combination with temozolomide is limited and requires further studies.
Participant Demographics
Adult patients with unresectable metastatic malignant melanoma.
Statistical Information
P-Value
0.012
Confidence Interval
95% ci: 1.07 to 1.75
Statistical Significance
p<0.036
Want to read the original?
Access the complete publication on the publisher's website